USPTO serial 97381068
AVERITAS PHARMA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEE, CATHERINE ANNE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AVERITAS PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Paul C. Llewellyn
Paul C. Llewellyn ARNOLD & PORTER KAYE SCHOLER LLP250 WEST 55TH STREETNEW YORK, NY 10019-9710United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of inflammation and gout; vaccines; sanitary preparations for medical purposes; dietetic substances to support nutritional balance and to treat deficiencies, namely, vitamins, mineral supplements, and probiotic preparations adapted for medical use; Wound dressings; surgical dressings; bandages, medical adhesive patches and medical adhesive tapes for dressings; medical adhesives to bind wounds; bandages, medical adhesive patches, medical adhesive tapes and medical adhesives to close skin wounds, incisions and cuts | ACTIVE | — |
| 041 | Conducting of training courses in the field of medicine and pharmaceuticals; issuance and publication of books, journals and other communication media in print and electronic form, namely, publishing and issuing of books, journals and scientific papers in the field of medicine and pharmaceuticals, especially for pharmaceutical companies, pharmacists, physicians, patients, health insurance companies and their professional associations | ACTIVE | — |
| 042 | Scientific and technological services and research in the medical and pharmaceutical field, namely, pharmaceutical product development, product development of medical devices, development of healthcare software, development of healthcare informatics services and scientific study and research services in the fields of medicine and the prevention, treatment and management of illnesses, diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Averitas Pharma, Inc.
- Other trademarks owned by Averitas Pharma, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named AVERITAS PHARMA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 23, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 23, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 5, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 5, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 20, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 20, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 13, 2024 | NOAC | CORRECTED NOA E-MAILED | — |
| Aug 13, 2024 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Aug 7, 2024 | IROA | RESPONSE TO ITU OFFICE ACTION ENTERED | — |
| Aug 7, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 7, 2024 | INCD | ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST | — |
| Jun 11, 2024 | INCD | ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST | — |
| Jun 10, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 3, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 2, 2024 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| May 2, 2024 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| May 2, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 2, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 2, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 22, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 20, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 20, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 20, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 23, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 28, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 28, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 8, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 21, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 21, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 21, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 21, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 21, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 14, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 29, 2022 | NWAP | NEW APPLICATION ENTERED | — |